Expert Opin Emerg Drugs. 2025 Nov 12. doi: 10.1080/14728214.2025.2590155. Online ahead of print.
ABSTRACT
INTRODUCTION: Immune thrombocytopenia (ITP) is an autoimmune disorder leading to low platelet counts and increased bleeding risk. The management of ITP, particularly in chronic or refractory cases, presents ongoing challenges, necessitating the development of novel therapeutic approaches that target its complex immunopathophysiology.
AREAS COVERED: This review evaluates the current ITP treatment landscape, including established first-line and second-line therapies, and provides an in-depth analysis of emerging drug classes. Key areas include neonatal Fc receptor inhibitors, Bruton’s tyrosine kinase inhibitors, spleen tyrosine kinase inhibitors, complement inhibitors, and novel immunotherapies. The scientific rationale, clinical trial data, efficacy, safety profiles, and potential positioning of these agents in future ITP management algorithms are discussed. The literature search encompassed PubMed, Embase, and clinical trial registries for articles and data published up to early 2025.
EXPERT OPINION: Therapeutic options for ITP are rapidly expanding beyond conventional immunosuppressants and splenectomy. Emerging targeted therapies offer the promise of improved efficacy, better safety profiles, and the potential for durable, treatment-free remission. Future research should focus on personalized medicine approaches, biomarker identification for predicting treatment response, optimizing treatment sequencing, and understanding long-term outcomes to transform ITP care.
PMID:41223379 | DOI:10.1080/14728214.2025.2590155
